PBYI Puma Biotechnology Inc
6,890
$4.73
$0.21
(4.25%)
| Watchers | 6,890 |
| 52-Wk Low | $2.13 |
| 52-Wk High | $7.73 |
| Market Cap | $238.3M |
| Volume | 247,796.00 |
| 52-Wk High | $7.73 |
| 52-Wk Low | $2.13 |
Puma Biotechnology Reports First Quarter Financial ResultsBusiness Wire • 13 days ago
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2024. Unless otherwise stated, all comparisons are for the...
Share to Feed
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 2, 2024, following the release of its first quarter...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 2, 2024, the Compensation Committee of Pumas Board of Directors approved the grant of an inducement...
For the last three days, A.I.dvisor has detected that PBYI's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
For the last three days, A.I.dvisor has detected that PBYI's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
In recent trading, shares of Puma Biotechnology Inc (PBYI) have crossed above the average analyst 12-month target price of 5.00, changing hands for 5.35/share. When a stock reaches the...
For the last three days, A.I.dvisor has detected that PBYI's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
For the last three days, A.I.dvisor has detected that PBYI's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
This is a signal that PBYI's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational New Drug Application...